337 related articles for article (PubMed ID: 22313616)
61. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
[TBL] [Abstract][Full Text] [Related]
62. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
63. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
64. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
[TBL] [Abstract][Full Text] [Related]
65. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
Herr HW; Dalbagni G
J Urol; 2003 May; 169(5):1706-8. PubMed ID: 12686813
[TBL] [Abstract][Full Text] [Related]
66. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
67. Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
Denzinger S; Burger M; Fritsche HM; Bertz S; Hofstädter F; Wieland WF; Hartmann A; Otto W
Scand J Urol Nephrol; 2009; 43(4):282-7. PubMed ID: 19382004
[TBL] [Abstract][Full Text] [Related]
68. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin.
Bilen CY; Inci K; Erkan I; Ozen H
J Urol; 2003 May; 169(5):1702-5. PubMed ID: 12686812
[TBL] [Abstract][Full Text] [Related]
69. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
70. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
[TBL] [Abstract][Full Text] [Related]
71. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].
Nguyen-Huu Y; Delorme G; Lillaz J; Bedgedjian I; Le Ray-Ferrières I; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
Prog Urol; 2012 May; 22(5):284-90. PubMed ID: 22515925
[TBL] [Abstract][Full Text] [Related]
72. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
[TBL] [Abstract][Full Text] [Related]
73. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
[TBL] [Abstract][Full Text] [Related]
74. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
[TBL] [Abstract][Full Text] [Related]
75. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?
Decobert M; LaRue H; Harel F; Meyer F; Fradet Y; Lacombe L
Cancer; 2008 Aug; 113(4):710-6. PubMed ID: 18543328
[TBL] [Abstract][Full Text] [Related]
76. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
77. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
78. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
[TBL] [Abstract][Full Text] [Related]
79. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
[TBL] [Abstract][Full Text] [Related]
80. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
